XML 28 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Selected Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]  
Summary of Quarterly Results of Operations

A summary of our quarterly results follows:

 

(in thousands, except per share data)

First

Quarter

 

 

Second

Quarter

 

 

Third

Quarter

 

 

Fourth

Quarter

 

Year Ended December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenues

$

138,403

 

 

$

183,580

 

 

$

222,094

 

 

$

244,010

 

Total operating expenses (1)

$

239,400

 

 

$

149,119

 

 

$

131,996

 

 

$

195,289

 

Net (loss) income (1)

$

(102,115

)

 

$

51,338

 

 

$

53,789

 

 

$

34,000

 

Net (loss) income per share, basic (1)

$

(1.12

)

 

$

0.56

 

 

$

0.59

 

 

$

0.37

 

Net (loss) income per share, diluted (1)

$

(1.12

)

 

$

0.54

 

 

$

0.56

 

 

$

0.35

 

Weighted average common shares outstanding, basic

 

91,056

 

 

 

91,389

 

 

 

91,859

 

 

 

92,182

 

Weighted average common shares outstanding, diluted

 

91,056

 

 

 

94,779

 

 

 

96,074

 

 

 

97,229

 

blank

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 2018:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenues

$

71,086

 

 

$

96,905

 

 

$

151,757

 

 

$

131,492

 

Total operating expenses

$

108,533

 

 

$

98,757

 

 

$

97,434

 

 

$

109,621

 

Net (loss) income

$

(41,818

)

 

$

(5,913

)

 

$

50,764

 

 

$

18,078

 

Net (loss) income per share, basic

$

(0.47

)

 

$

(0.07

)

 

$

0.56

 

 

$

0.20

 

Net (loss) income per share, diluted

$

(0.47

)

 

$

(0.07

)

 

$

0.52

 

 

$

0.19

 

Weighted average common shares outstanding, basic

 

89,526

 

 

 

90,100

 

 

 

90,555

 

 

 

90,742

 

Weighted average common shares outstanding, diluted

 

89,526

 

 

 

90,100

 

 

 

96,798

 

 

 

95,724

 


(1) In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.